Products and Services

IMMUPEL

LCT’s microcapsule technology, IMMUPEL™, isolates the transplanted cells from the patient’s immune system and eliminates the need for toxic immunosuppressant drugs. Encapsulation permits oxygen and nutrients to diffuse inwards to maintain cell viability, while secreted cell products are able to exit and exert the desired benefit.

IMMUPEL
 Nanoporous alginate microspheres

LCT has developed an alginate-polyornithine microcapsule technology. This process is a crucial component of LCT’s novel cell therapy approach for treating disease. The seaweed-derived (alginate) coating isolates the transplanted cells from the patient’s immune system and eliminates the need for toxic immunosuppressant drugs. Encapsulation permits oxygen and nutrients to diffuse inwards to maintain cell viability, while secreted cell products are able to exit and exert the desired benefit. LCT selects alginate of defined chemical and physical characteristics, which is purified to GMP standards for cell encapsulation.

Peer-Reviewed Technology

A scientific paper reviewing LCT’s biocapsule technology is published in the international journal, BioMaterials. This signifies academic acceptance of the rigorous development of testing methodologies for characterisation and refinement of the process.

Applications

LCT’s biocapsule can be used for stem cells, cell lines or primary cells. It is suitable for applications that require physical and kinetic flexibility in delivery, since the basic properties of the biocapsule can be maintained while tailoring the system to the desired application, including membrane characteristics like flux, wall strength, dose and biocompatibility. LCT has published data demonstrating the use of encapsulated choroid plexus cells in animal models of neurodegenerative diseases such as Parkinson’s disease, Huntington’s disease, Stroke and hearing loss.

Encapsulation technology is available for license.  For more information please contact us at bizdev@lctglobal.com.


Publications